Mavorixafor is a small molecule commercialized by X4 Pharmaceuticals, with a leading Phase III program in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis). According to Globaldata, it is involved in 13 clinical trials, of which 7 were completed, 2 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Mavorixafor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Mavorixafor is expected to reach an annual total of $169 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Mavorixafor (X4P-001) is under development for the treatment of severe congenital neutropenia, Waldenstrom’s Macroglobulinemia, WHIM syndrome, melanoma and refractory solid tumors including clear cell renal cell carcinoma (ccRCC) and triple-negative breast cancer. It is administered through oral route. The drug candidate was under development for the treatment of human immunodeficiency virus (HIV) Infections (AIDS). The drug candidate acts by targeting C-X-C receptor type 4 (CXCR4).
X4 Pharmaceuticals Overview
X4 Pharmaceuticals, formerly Arsanis, is a clinical stage bio pharmaceutical company that develops oral, small molecule therapeutics to treat cancer and rare diseases. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of Warts, Hypogammaglobulinemia, Immunodeficiency and Myelokathexis (WHIM) syndrome X4P-002 and X4P-003, small molecule antagonists of chemokine receptor CXCR4 for treating glioblastoma multiforme and primary immune deficiencies (PI’s). The company is developing oral allosteric antagonists of CXCR4 in order to block overstimulation of the CXCL12/CXCR4 pathway that enables trafficking of immune cells and effective immunosurveillance. X4 is headquartered in Cambridge, Massachusetts, the US..
The operating loss of the company was US$85.1 million in FY2021, compared to an operating loss of US$60 million in FY2020. The net loss of the company was US$88.7 million in FY2021, compared to a net loss of US$62.1 million in FY2020.
For a complete picture of Mavorixafor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.